DDIT3 and T-cell non-Hodgkin lymphoma: In patients with aggressive B-cell or T-cell lymphomas (primarily DLBCL), those with positive iPET after 2 cycles of R-CHOP were randomized to receive either an intensive Burkitt-like regimen or to continue with the induction of R-CHOP for an additional four cycles [60].